Abstract 19P
Background
Polo-like kinase 1 (PLK1) is a protein kinase plays an important role in the initiation, maintenance, and completion of mitotic process. Human PLK1 has been shown to be over-expressed in a variety of human cancers, and elevated levels of PLK1 have been associated with poor prediction, leading to an attractive target for anticancer therapy.
Methods
A novel Silymarin functionalized FeO quantum cores (SiFeO QDs) were synthesized through one step synthesis method. For in vitro assay MTT, apoptotic staining assays and cell cycle analysis were performed. In vivo studies, xenocraft mice further administration of the SiFeO QDs at a dose of 25mg/kg body weight every other day for 14d. after 24h of the last treatment dose, the mice were left to monitor their survival or sacrificed to assess the antitumor activity.
Results
SiFeO QDs inhibited proliferation of Triple negative breast cancer cell lines, with mean inhibitory concentration of (IC50) value about 4.5µg/ml, meanwhile in non-dividing normal cells, it didn’t exhibit any adverse effects upto 50µg/ml. In animal models, administration of SiFeO QDs significantly inhibited the growth of MM2 breast cancer xenografts. It also accompanied by decreased expression of anti-apoptotic proteins, BCL-2, and MCL-1 and increased expression of BAX. Moreover, caspase-3 was activated to a greater extent after SiFeO QDs treatment. Impressively the treated group animal exihibit there is no aberrant effect in vital organs and blood parameters. Tumor growth was significantly inhibited after i.v. injection of SiFeO QDs at dose of 5mg/kg compared to free FeO QDs at dose of 25mg/kg. However, this system remarkably suppressed tumor growth in human breast cancer xenografts.
Conclusions
The significant antitumor efficacy of SiFeO QDs were attributed to the ability of the cores to show both prolonged blood circulation and high accumulation in tumors, as confirmed by near infrared (NIR) imaging systems. Taken all together, the SiFeO QDs hold great potential in biomedical applications especially cancer theranostics due to their versatile nature in therapy as well in diagnostics in clinical tumor biology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Manickam Paulpandi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
15P - Comparing the outcomes of the mastectomy using the tumescent technique by between the special and non-special surgeons
Presenter: Naoya Takeda
Session: Poster display session
Resources:
Abstract
16P - Risk factors and prognostic value of non-alcoholic fatty liver disease (NAFLD) in hormone positive, non-metastatic breast cancer receiving adjuvant hormonal therapy
Presenter: Kartika Taroeno Hariadi
Session: Poster display session
Resources:
Abstract
17P - Distance related outcome in indigenous and non-indigenous breast cancer women of Western Australia
Presenter: Azim Khan
Session: Poster display session
Resources:
Abstract
18P - Usefulness of neutrophil to lymphocyte ratio in early stage breast cancer as predictor of disease-free survival in a Babylon Oncology Center
Presenter: Yaala Raof Al-Bairmany
Session: Poster display session
Resources:
Abstract
20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis
Presenter: Amir Shamshirian
Session: Poster display session
Resources:
Abstract
21P - Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
Presenter: Than Than Aye
Session: Poster display session
Resources:
Abstract
22P - Clinical outcomes after skin-sparing or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy in early breast cancer patients
Presenter: Hye Yoon Lee
Session: Poster display session
Resources:
Abstract
23P - The correlations between knowledge and attitudes of productive age women toward “SADARI” (breast self-assessment) as early detection of breast cancer in Pejeng Kaja Village, Ubud, Bali
Presenter: Yorky Brahmantya
Session: Poster display session
Resources:
Abstract
24TiP - KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer
Presenter: Fatima Cardoso
Session: Poster display session
Resources:
Abstract
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract